 efficaci low-molecular-weight heparin manag intermitt claudic chronic arteri occlus diseas heparin controversi risk long-term anticoagul therapi low molecular weight lmw heparin mw dalton Xa factor minim risk hemorrhag new possibl prevent treatment venou acut arteri thromboembol therefor patient intermitt claudic double-blind studi twenty-two month singl daili subcutan dose uaxa lmw heparin placebo way period time month lmw heparin treatment improv walk capac pain-fre walk time hemorrheolog pattern fibrinogen concentr whole blood viscos low shear rate lmw heparin antithrombot profibrinolyt effect anti-xa factor plasminogen activ partial thromboplastin time lmw heparin-tr patient noteworthi side effect result lmw heparin use drug long-term treatment chronic arteri occlus diseas limb